1. Home
  2. MDXH vs NHS Comparison

MDXH vs NHS Comparison

Compare MDXH & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • NHS
  • Stock Information
  • Founded
  • MDXH 2003
  • NHS 2003
  • Country
  • MDXH Belgium
  • NHS United States
  • Employees
  • MDXH N/A
  • NHS N/A
  • Industry
  • MDXH
  • NHS Trusts Except Educational Religious and Charitable
  • Sector
  • MDXH
  • NHS Finance
  • Exchange
  • MDXH Nasdaq
  • NHS Nasdaq
  • Market Cap
  • MDXH 203.4M
  • NHS 226.7M
  • IPO Year
  • MDXH 2021
  • NHS N/A
  • Fundamental
  • Price
  • MDXH $4.92
  • NHS $7.52
  • Analyst Decision
  • MDXH Buy
  • NHS
  • Analyst Count
  • MDXH 1
  • NHS 0
  • Target Price
  • MDXH $6.00
  • NHS N/A
  • AVG Volume (30 Days)
  • MDXH 274.6K
  • NHS 111.8K
  • Earning Date
  • MDXH 11-12-2025
  • NHS 01-01-0001
  • Dividend Yield
  • MDXH N/A
  • NHS 13.44%
  • EPS Growth
  • MDXH N/A
  • NHS N/A
  • EPS
  • MDXH N/A
  • NHS N/A
  • Revenue
  • MDXH $98,953,000.00
  • NHS N/A
  • Revenue This Year
  • MDXH $24.43
  • NHS N/A
  • Revenue Next Year
  • MDXH $21.00
  • NHS N/A
  • P/E Ratio
  • MDXH N/A
  • NHS N/A
  • Revenue Growth
  • MDXH 22.56
  • NHS N/A
  • 52 Week Low
  • MDXH $1.35
  • NHS $6.95
  • 52 Week High
  • MDXH $5.33
  • NHS $9.17
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 64.64
  • NHS 56.80
  • Support Level
  • MDXH $4.71
  • NHS $7.14
  • Resistance Level
  • MDXH $5.33
  • NHS $7.37
  • Average True Range (ATR)
  • MDXH 0.30
  • NHS 0.11
  • MACD
  • MDXH 0.05
  • NHS 0.03
  • Stochastic Oscillator
  • MDXH 72.11
  • NHS 86.56

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

Share on Social Networks: